Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Total Voting Rights
Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, announces that for the purpose of the FCA's Disclosure and Transparency Rules, the Company's issued share capital consists of 92,298,816 Ordinary Shares of ordinary shares of 0.2p each, with voting rights ("Ordinary Shares"). The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 92,298,816.
The Company's issued share capital consists of 92,298,816 Ordinary Shares and this number should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
-ENDS-
ENQUIRIES
| Induction James Balmain, Chief Executive Officer | Via Walbrook PR Ltd: induction@walbrookpr.com |
| Guy Mitchell, Chief Financial Officer | |
| | |
| Singer Capital Markets (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
| Philip Davies / Kailey Aliyar | |
| | |
| Walbrook PR Ltd | +44 (0)20 7933 8780 |
| Alice Woodings / Stephanie Cuthbert | |
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transform care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
